By


Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes
Read more here

By


Merganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides
Read more here

 

 

By


Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase
One Study of Novel NMDA Receptor Antagonist d-Methadone
Read more here

By


Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone
Read more here

By


Ossianix Expands and Extends its Research Collaboration with Lundbeck on CNS Therapeutics
Read More Here

By


Melior Discovery Awarded SBIR Grant for Studying MLR-1023 Mechanism of Action
Read more here

By


Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone
Read more here

By


Novira Therapeutics Announces Presentation of Phase Ia Safety and Pharmacokinetic Data for NVR 3-778
Read more here

By


Relmada Therapeutics Appoints Michael Becker as Senior Vice President of Finance and Corporate Development
Read more here